Immunogenic insights and experimental validation of a multiepitope vaccine construct against Streptococcus pneumoniae

Area of Science:

• Bacteriology
• Vaccinology
• Immunology

Background:

• *Streptococcus pneumoniae* is a leading cause of severe infections like pneumonia and meningitis, particularly in vulnerable populations.
• *Antibiotic resistance* and the emergence of non-vaccine serotypes diminish the effectiveness of current treatments and vaccines.
• Existing polysaccharide vaccines offer limited serotype coverage, necessitating the development of broader-protection strategies.

Purpose of the Study:

• To experimentally validate a computationally designed multi-epitope vaccine candidate against *Streptococcus pneumoniae*.
• To assess the safety, immunogenicity, and efficacy of this novel vaccine construct.

Main Methods:

• The multi-epitope vaccine construct was expressed in *Escherichia coli* and purified using Ni-NTA affinity chromatography.
• Protein characterization involved SDS-PAGE, Western blot, and circular dichroism spectroscopy.
• Immunogenicity and safety were evaluated in BALB/c mice through antibody response assays (Western blot, ELISA), cytokine profiling, and hemolysis assays.

Main Results:

• The purified vaccine protein's structure aligned with computational predictions.
• Hemolysis assays confirmed the vaccine's safety and tolerability.
• Administration in mice induced significant antibody titers and a broad cytokine response, including interleukins, TNF-α, and GM-CSF.

Conclusions:

• This study presents the first experimental validation of a designed multi-epitope vaccine against *S. pneumoniae*.
• The vaccine demonstrated promising immunogenicity, characterized by antibody production and a significant cytokine profile.
• The absence of hemolytic toxicity supports its potential as a safe and effective vaccine candidate.